Sarepta Therapeutics (SRPT) Share-based Compensation (2010 - 2026)

Sarepta Therapeutics' Share-based Compensation history runs 16 years deep, the most recent figure standing at -$109.1 million for Q4 2025.

• In Q4 2025, Share-based Compensation fell 319.48% year-over-year to -$109.1 million; the TTM figure through Mar 2026 stood at -$51.1 million (down 148.62% YoY), while the FY2025 annual figure was $218.0 million, down 8.6% from the prior year.
• Share-based Compensation for Q4 2025 stood at -$109.1 million, down from $16.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $102.9 million in Q2 2022, with the low at -$109.1 million in Q4 2025.
• The 5-year median for Share-based Compensation is $41.4 million (2023), against an average of $26.4 million.
• Peak annual rise in Share-based Compensation reached 395.64% in 2025, while the deepest fall reached 319.48% in 2025.
• Sarepta Therapeutics' Share-based Compensation stood at -$70.9 million in 2021, then surged by 171.21% to $50.5 million in 2022, then retreated by 9.3% to $45.8 million in 2023, then gained by 8.48% to $49.7 million in 2024, then tumbled by 319.48% to -$109.1 million in 2025.
• Business Quant data shows SRPT's Share-based Compensation at -$109.1 million in Q4 2025, $16.4 million in Q3 2025, and $41.6 million in Q2 2025.